Trial Profile
A Phase III Randomized Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Doxorubicin liposomal (Primary)
- Indications Carcinoma; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 12 Jun 2012 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 12 Jun 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 29 Dec 2009 Final survival results published in Gynecologic Oncology.